Cas No.: | 1624602-30-7 |
Chemical Name: | VR-23,VR 23 |
Synonyms: | VR-23,VR 23 |
SMILES: | N1C2C(=CC=C(Cl)C=2)C(N2CCN(S(C3=CC=C([N+]([O-])=O)C=C3[N+]([O-])=O)(=O)=O)CC2)=CC=1 |
Formula: | C19H16ClN5O6S |
M.Wt: | 477.88 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | VR23 is a small molecule that potently inhibited the activities of trypsin-like proteasomes (IC50 = 1 nM), chymotrypsin-like proteasomes (IC50 = 50-100 nM), and caspase-like proteasomes (IC50 = 3 μM). |
In Vivo: | VR23 shows effective antitumor and antiangiogenic activities in mice. |
In Vitro: | VR23 is a novel proteasome inhibitor targeting β2 of the 20S proteasome subunit. VR23 produces a synergistic effect in killing multiple myeloma cells, including those that were resistant to bortezomib. VR23 as a structurally novel proteasome inhibitor with desirable properties as an anticancer agent. |